利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.065 秒)

    Soluble interleukin-1 receptor accessory molecule
    4.
    发明申请
    Soluble interleukin-1 receptor accessory molecule 失效
    可溶性白细胞介素-1受体辅助分子

    公开(公告)号：US20050171337A1

    公开(公告)日：2005-08-04

    申请号：US11066006

    申请日：2005-02-25

    申请人： Daniel Bednarik ,  Henrik Olsen ,  Craig Rosen

    发明人： Daniel Bednarik ,  Henrik Olsen ,  Craig Rosen

    IPC分类号： C07H21/04 ,  C07K14/00 ,  C07K14/715 ,  C12N1/20 ,  C12N15/00 ,  C12N15/85

    CPC分类号： C07H21/04 ,  C07K14/7155

    摘要： The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein. IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are futher provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.

    摘要翻译： 本发明涉及作为Ig超家族成员的新型可溶性IL-1受体辅助分子（IL-1RACM）蛋白质。 特别地，提供编码人IL-1R AcM蛋白的分离的核酸分子。 还提供IL-1R AcM多肽，载体，宿主细胞和用于制备它们的重组方法。 提供筛选方法用于鉴定IL-1信号转导的激动剂和拮抗剂。 本发明还涉及用IL-1R AcM拮抗剂治疗生理和病理疾病状况的方法。

    Heart failure gene determination and therapeutic screening
    5.
    发明申请
    Heart failure gene determination and therapeutic screening 审中-公开
    心力衰竭基因测定和治疗筛选

    公开(公告)号：US20060275770A1

    公开(公告)日：2006-12-07

    申请号：US10547931

    申请日：2003-11-26

    申请人： Daniel Bednarik

    发明人： Daniel Bednarik

    IPC分类号： C12Q1/68 ,  G01N33/53 ,  G01N33/00

    CPC分类号： G01N33/5308 ,  C12Q1/6883 ,  C12Q1/6897 ,  C12Q2600/158

    摘要： Genes implicated in the progression of heart failure and in the endogenous myocardial recovery and repair mechanism provide the basis for screening potential therapeutic compounds for use as pharmaceutical preparations for the treatment of congestive heart failure. Target genes or target gene products whose expression level or biological activity are altered by a potential therapeutic compound can be validated functionally, by determining the physiological effect(s) precipitated by compound-induced changes in gene expression or biological activity of gene products. In particular, changes in the expression of the target gene(s) or in the biological activity of target gene product(s) can be correlated with indices of cardiac function, and a potential therapeutic compound that causes a therapeutically significant change such expression or activity warrants further clinical investigation as a drug candidate.

    摘要翻译： 涉及心力衰竭进展和内源性心肌恢复和修复机制的基因为筛选用作治疗充血性心力衰竭的药物制剂的潜在治疗化合物提供了基础。 可以通过确定由化合物诱导的基因表达变化或基因产物的生物活性沉淀的生理作用，功能性地验证其表达水平或生物活性被潜在的治疗化合物改变的靶基因或靶基因产物。 特别地，目标基因的表达或目标基因产物的生物活性的变化可以与心脏功能的指标相关联，并且潜在的治疗化合物引起治疗上显着的变化，这种表达或活性 保证进一步的临床调查作为候选药物。